These results align well with our findings in the CyTOF dataset, which mainly revolve around the high correlation of EpCAM and HLA-DR protein expression in indolent tumors and highlight the potential of MHC-II expression in cancer cells as an independent biomarker of sensitivity to checkpoint inhibitors. This evidence concerns the gene EPCAM and cancer.